Robotic transversus abdominis release (TAR) for ventral hernia repairs is associated with low surgical site occurrence rates and length of stay despite increasing modifiable comorbidities.

Autor: Skoczek AC; Edward Via College of Osteopathic Medicine - Auburn, 910 S Donahue Dr., Auburn, AL, 36830, USA. askoczek@auburn.vcom.edu., Ruane PW; Edward Via College of Osteopathic Medicine - Carolinas, Spartanburg, SC, USA., Holland AB; Edward Via College of Osteopathic Medicine - Carolinas, Spartanburg, SC, USA., Hamilton JK; Lincoln Memorial University DeBusk College of Osteopathic Medicine - Knoxville, Knoxville, TN, USA., Fernandez DL; Crestwood Medical Center, Huntsville, AL, USA.
Jazyk: angličtina
Zdroj: Hernia : the journal of hernias and abdominal wall surgery [Hernia] 2024 Oct; Vol. 28 (5), pp. 1727-1735. Date of Electronic Publication: 2024 May 01.
DOI: 10.1007/s10029-024-03044-6
Abstrakt: Purpose: Modifiable comorbidities (MCMs) have previously been shown to complicate postoperative wound healing occasionally leading to surgeon hesitancy to repair ventral hernias prior to preoperative optimization of comorbidities. This study describes the effects of MCMs on surgical site occurrences (SSOs) and hospital length of stay (LOS) following robotic transversus abdominis release (TAR) with poly-4-hydroxybutyrate (P4HB) resorbable biosynthetic mesh retromuscular sublay for ventral hernia repair in patients who had not undergone preoperative optimization.
Methods: A single-surgeon retrospective review was performed for patients who underwent the robotic TAR procedure with P4HB mesh between January 2015 and May 2022. Patients were stratified by the amount of MCMs present: 0, 1, or 2 + . MCMs included obesity, diabetes, and current tobacco use. Patient data was analyzed for the first 60 days following their operation. Primary outcomes included 60-day SSO rates and hospital LOS.
Results: Three hundred and thirty-four subjects met the inclusion criteria for SSO and prolonged LOS analysis. 16.8% had no MCM, 56.1% had 1 MCM, and 27% had 2 + MCMs. No significant difference in SSO was seen between the 3 groups; however, having 2 + MCMs was significantly associated with increased odds of SSO (odds ratio 3.25, P = .019). When the groups were broken down, only having a history of diabetes plus obesity was associated with significantly increased odds of SSO (odds ratio 3.54, P = .02). No group showed significantly increased odds of prolonged LOS.
Conclusion: 2 + MCMs significantly increase the odds of SSO, specifically in patients who have a history of diabetes and obesity. However, the presence of any number of MCMs was not associated with increased odds of prolonged LOS.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: